66573-60-2

Upstream product

• 110-91-8 morpholine 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 143-33-9 sodium cyanide 

Downstream Products

• 66548-85-4 4-cyano-4-morpholin-4-yl-4-(4-trifluoromethyl-phenyl)-butyric acid ethyl ester 

Relevant academic research and scientific papers

Oxygenated heterocyclic compounds, pharmaceutical compositions containing them

Compounds having antiparasitic properties are 1,2,4-trioxanes of the formula: in which:, R1 and R2 together with the adjacent carbon atom form a cycloalkyl group which may be interrupted by an oxygen atom;, R3 is a hydrogen atom or a hydroxyl gorup or eth

Steric Inhibition of Synergistic Radical Stabilizing Effects

Equilibrium acidities in Me2SO for 14 α-N-morpholinyl-, 6 α-N-piperidinyl-, and 7 α-cyclohexylarylacetonitriles and the oxidation potentials of their conjugate bases have been determined.The increased pKHA values by about 2 units observed in these systems, relative to the corresponding arylacetonitriles, is ascribed to the presence of increased steric constraints in the anions.Hammett plots revealed larger ρ values than for arylacetonitriles (6-7 versus 5.5), pointing to an increased negative charge density on the benzylic carbon atoms in the anions.A plot of anion oxidation potentials, Eox(A-), versus pKHA for the α-N-morpholinylarylacetonitriles was linear with a slope near unity, showing that remote substituents for the most part have very little effect on radical stabilities.A 5 and 6 kcal/mol lowering of the BDE of the acidic C-H bond caused by replacing the cyclohexyl group in α-cyclohexylphenylacetonitrile by α-N-morpholinyl or N-piperidinyl groups, respectively, is attributed to the strong donor properties of these amino functions.The effects are only about one-third as large, however, as similar effects in R2NCH2COPh, where the steric effect of Ph is absent and a synergistic effect is believed to be operative.

Method for treating anxiety in mammals

This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.

6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents

This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.